MITOXANTRONE, 5-FU, AND LEUCOVORIN IN BREAST-CANCER

被引：2
|
作者：
SWAIN, SM
HONIG, SF
机构：
[1] Lombardi Cancer Research Center, Department of Medicine, Division of Medical Oncology, Washington, District of Columbia
来源：
MEDICAL AND PEDIATRIC ONCOLOGY | 1994年 / 22卷 / 06期
关键词：
MITOXANTRONE; 5-FLUOROURACIL; LEUCOVORIN; CHEMOTHERAPY OF BREAST CANCER;
D O I：
10.1002/mpo.2950220603
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Eighteen patients (17 evaluable for response) with metastatic breast cancer were treated with mitoxantrone 10 mg/m(2) day 1, followed by 5-fluorouracil 375 mg/m(2) day 1-5, and high-dose leucovorin 500 mg/m(2) day 1-5 given every 28 days. There was one complete and four partial responses for an objective response rate of 30% and 41% stable disease. The major toxicities were hematologic and gastrointestinal. This regimen has activity in metastatic breast cancer comparable to conventional and/or standard chemotherapy regimens for advanced disease. (C) 1994 Wiley-Liss, Inc.
引用
收藏
页码：370 / 374
页数：5
相关论文
共 50 条
  • [31] SALVAGE TREATMENT WITH CISPLATIN (CDDP) AND 5-FLUOROURACIL (5-FU) IN ADVANCED BREAST-CANCER PATIENTS
    PRONZATO, P
    AMOROSO, D
    BERTELLI, G
    LIONETTO, R
    ARDIZZONI, A
    CONTE, PF
    ROSSO, R
    GALLOTTI, P
    BREAST CANCER RESEARCH AND TREATMENT, 1987, 10 (01) : 108 - 108
  • [32] COMBINATION CHEMOTHERAPY IN METASTATIC BREAST-CANCER USING CYCLOPHOSPHAMIDE, ADRIAMYCIN, METHOTREXATE AND 5-FU (CAMF)
    LIPPMAN, AJ
    CUSTODIO, MC
    COHEN, FB
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1976, 17 (MAR): : 270 - 270
  • [33] CONTROL OF EMESIS BY INTRAVENOUS GRANISETRON IN BREAST-CANCER PATIENTS TREATED WITH 5-FU, EPIRUBICIN AND CYCLOPHOSPHAMIDE
    TAN, EH
    ANG, PT
    KHOO, KS
    SUPPORTIVE CARE IN CANCER, 1994, 2 (03) : 197 - 200
  • [34] Oral 5-FU analogues in the treatment of breast cancer
    Bunnell, CA
    Winer, EP
    ONCOLOGY-NEW YORK, 1998, 12 (10): : 39 - 43
  • [35] Safety of cisplatin combined with continuous 5-FU versus bolus 5-FU and leucovorin, in metastatic gastrointestinal cancer (FFCD 9404 randomised trial)
    Duffour, Jacqueline
    Bouche, Olivier
    Rougier, Philippe
    Milan, Chantal
    Bedenne, Laurent
    Seitz, Jean-Francois
    Buecher, Bruno
    Legoux, Jean-Louis
    Ducreux, Michel
    Vetrer, Denis
    Raoul, Jean-Luc
    Francois, Eric
    Ychou, Marc
    ANTICANCER RESEARCH, 2006, 26 (5B) : 3877 - 3883
  • [36] MITOXANTRONE, FLUOROURACIL PLUS L-LEUCOVORIN, AND VINORELBINE IN PRETREATED ADVANCED BREAST-CANCER
    COLLEONI, M
    NELLI, P
    GAION, F
    SGARBOSSA, G
    MANENTE, P
    ONCOLOGY, 1995, 52 (06) : 435 - 438
  • [37] Phase II study of oxaliplatin, 5-FU and leucovorin in patients with relapsed ovarian cancer
    Thomas, AL
    Osman, A
    Morgan, B
    Khanna, S
    Symonds, RP
    O'Byrne, K
    BRITISH JOURNAL OF CANCER, 2001, 85 : 57 - 57
  • [38] Irinotecan plus 5-FU and leucovorin in advanced colorectal cancer: North American trials
    Goldberg, RM
    Erlichman, C
    ONCOLOGY-NEW YORK, 1998, 12 (08): : 59 - 63
  • [39] Navelbine (N), leucovorin (L), and fluorouracil (5-FU) (FLN) for triple-negative metastatic breast cancer (TNBC)
    Zaniboni, A.
    Meriggi, F.
    Rizzi, A.
    Rota, L.
    Codignola, C.
    Di Biasi, B.
    Mazzocchi, M.
    Mutti, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [40] Combination of FOLFIRI (5-FU, Leucovorin, and Irinotecan) and ProAgio on colon cancer growth and metastasis
    Nagaraju, Purnachandra
    Foote, Jeremy B.
    Saddala, Madhu Sudhana
    Mishra, Falguni
    Sarvesh, Sujith
    Malla, Midhun
    Masood, Ashiq
    Liu, Zhi-Ren
    El-Rayes, Bassel F.
    CANCER RESEARCH, 2024, 84 (06)
12345